| Basics |
Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical business engaged in advancing novel RNA interference therapeutics and discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection.
|
| IPO Date: |
October 31, 2008 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$850.07M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.12 | 3.27%
|
| Avg Daily Range (30 D): |
$0.09 | 2.08%
|
| Avg Daily Range (90 D): |
$0.09 | 2.20%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.15M |
| Avg Daily Volume (30 D): |
.89M |
| Avg Daily Volume (90 D): |
.93M |
| Trade Size |
| Avg Trade Size (Sh.): |
205 |
| Avg Trade Size (Sh.) (30 D): |
107 |
| Avg Trade Size (Sh.) (90 D): |
119 |
| Institutional Trades |
| Total Inst.Trades: |
264 |
| Avg Inst. Trade: |
$1.61M |
| Avg Inst. Trade (30 D): |
$1.19M |
| Avg Inst. Trade (90 D): |
$1.23M |
| Avg Inst. Trade Volume: |
.46M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.89M |
| Avg Closing Trade (30 D): |
$.67M |
| Avg Closing Trade (90 D): |
$.87M |
| Avg Closing Volume: |
524.12K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-.04
|
$.01
|
$-.13
|
|
Diluted EPS
|
$-.04
|
$.01
|
$-.13
|
|
Revenue
|
$ .53M
|
$ 10.74M
|
$ 1.76M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -7.74M
|
$ 2.52M
|
$ -24.53M
|
|
Operating Income / Loss
|
$ -8.66M
|
$ 1.49M
|
$ -25.7M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -15M
|
$ .34M
|
$ .75M
|
|
PE Ratio
|
|
|
|
|
|
|
